Gene-editing company Beam Therapeutics is alleging that one of its scientists stole intellectual property and used it to co-found a Chinese company

Some lawmakers are urging the Trump administration to rethink a pending rule that may prevent Americans from obtaining medicines from licensed international pharmacies.

Novo has agreed to pay up to $2.6 billion to license an experimental, weekly weight loss pill from China’s Hengrui Pharma

Merck discontinued Recarbio, an important antibiotic in the U.S., despite concerns over resistance to superbugs.

Once promoted as tools to address obesity as a medical issue, GLP-1 drugs are increasingly being marketed as a way to look and feel better

With an eye toward pandemic preparedness, a U.N.-backed agency has signed sub-licensing deals related to generic versions of a Roche influenza treatment.

From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.

President Trump’s nominee to lead the FDA was grilled by senators on hot button topics like China, vaccines, and abortion access

A recent court decision in Indonesia sends an important message to other countries to challenge the pharma industry's use of "patent evergreening," patient advocates say.

During a Senate hearing today, Heidi Overton, the nominee to lead the FDA, plans to emphasize the need for speed and efficiency to compete with China

As of next month, a loophole that allows Americans to personally import their medications by mail is closing

For the second time this year, HHS announced new strategies to speed the away from animals in medical testing.

Western pharmaceutical companies are urging the Trump administration to allow them to keep doing deals with Chinese companies for drug candidates

From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.

The U.S. is working on rules for investing in China that would likely preserve pharma's ability to strike most licensing deals for Chinese drugs

The FDA is opening applications for a pilot program designed to shorten the time it takes for drugmakers to begin testing their products in humans

GSK has continued its drive to bulk up its pipeline, taking global rights to a multiple myeloma treatment developed in China

AstraZeneca disclosed that a breast cancer pill failed in a pivotal trial testing it as a first-line therapy in advanced tumors

From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.

Novartis investors are stepping up scrutiny of the company's dealmaking after setbacks to drugs it acquired through mergers and acquisitions

There has been rancorous debate over doctors accepting free gifts and speaking fees from pharma companies. That doesn't mean doctors have reconsidered.

A major Novartis shareholder has called for a shake-up of the drugmaker's board after its shares suffered a record fall following trial setbacks

An AstraZeneca drug reduced the dangerous flare-ups that worsen COPD in a pair of late-stage trials

The FDA warned a supplier of active pharma ingredients about residue on walls, a corroded product line, and open-toed sandals at its facility. It also included photos.

From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.

Pharma news from the Pharmalot campus, brought to you by the Pharmalittle newsletter

The FDA approved a life-extending treatment for advanced pancreatic cancer from Revolution Medicines that is the first to attack a genetic cause

About 14% of employers in the U.S. have already or plan to drop coverage of GLP-1 drugs in 2027, as companies see ​rising health care costs

Turkish regulators are investigating Teva Pharmaceutical for allegedly manipulating the patent system and disparaging rival drugs.

Democratic senators said RFK Jr.'s recent explanation of how he disposed of a financial stake in Gardasil litigation conflicts with his earlier answers

President Trump’s pledge to make pricey weight loss drugs widely available for low-income Americans through Medicaid is not panning out

From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.

Roche's Genentech will invest $750 million to double the size of its existing production facility in Oregon

A Regeneron drug for an ultra-rare disease that causes bone to grow where it shouldn't won U.S. regulatory approval, capping a three-decade effort

President Trump is expected to nominate Heidi Overton, White House deputy director of domestic policy, to serve as the next FDA commissioner

In its effort to lower drug prices, the White House has declared "promises made, promises kept." That's a narrative that doesn't reflect the full story.

Eyepoint disclosed that a Phase 3 trial of its experimental treatment for a common cause of age-related blindness fell short of its primary goal

AstraZeneca is discontinuing a late-stage drug trial in patients with metastatic non-small cell lung cancer, extending a run of setbacks

From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.

The FDA approved a Bristol oral treatment for advanced multiple myeloma, marking the debut of a new class of medicine for the blood cancer

A lab that tussled with regulators over impurities found in widely used medicines has accused U.S. Pharmacopeia of making false and misleading remarks about its methods.

Seven months after the launch of its own low-cost insulin brand, California has distributed more than 120,000 five-pen packs of insulin glargine priced at $55 each

Eli Lilly filed six lawsuits against U.S. companies it accuses of illegally selling black-market versions of its experimental obesity drug retatrutide

The FDA rejected a radiopharmaceutical therapy because of manufacturing issues, halting what would have been a competitor for Novartis

Sanofi is experiencing shortages of two medicines used to treat Pompe disease after the FDA warned the company over manufacturing issues

Sanofi is experiencing shortages of two medicines for Pompe disease, alarming patient groups.

From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.

Eli Lilly and Novo Nordisk convinced a federal judge to toss an antitrust lawsuit by a compound pharmacy

In today's Pharmalittle newsletter: Moderna's mRNA flu shot approved, a death reported in a gene-editing trial in China, and more.

In today's Pharmalittle newsletter, a Medicare pilot and orphan drugs, Pfizer cutbacks, and more.